Moderna's Cancer Vaccine Breakthrough & Why Uber Could Win the Robotaxi War
Moderna (NASDAQ:MRNA) is back in the headlines after phase three success for what's being called a cancer vaccine, built on the same mRNA technology that powered its Covid vaccine. We discuss just how significant it is that this treatment has gotten this far in trials, why the pandemic accelerated mRNA research faster…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Stock Club
See all episodes →Ireland's New Investment Tax Scheme Explained & An AI Pick from Investicon
Motley Fool Co-Founder David Gardner's Top 10 Stock Picks, One Is Up 138,000% | Stock Club 325
Chapters Group: Europe's Mini Constellation Software With Compounding Quality's Pieter Slegers
Similar episodes from other shows
More like Stock Club →
No Artificial Sweetener for Uber
Uber CEO Dara Khosrowshahi on self-driving's future, changing business model, job displacement
Mark Mulhern (Manu Invests) on Autonomous Taxis and the Buying Opportunity in Uber
Self-Driving Cars: From 7,000 to 6 million Robotaxis | The Decade Ahead
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.